AFSOS-SFRO-SFH-SFNEP-SFCE-GFRP guidelines on radio-induced nausea and vomiting.

Area of Science:

• Oncology
• Radiotherapy
• Clinical Practice Guidelines

Background:

• Radiation-induced nausea and vomiting (RINV) is a common side effect of radiotherapy, with prevalence ranging from 40% to 80%.
• RINV significantly impacts patient treatment adherence, quality of life, and can exacerbate comorbidities.
• Current management strategies for RINV are often inconsistent, necessitating standardized clinical guidelines.

Purpose of the Study:

• To establish comprehensive clinical practice guidelines for the effective management of radiation-induced nausea and vomiting.
• To provide healthcare professionals with evidence-based recommendations for RINV prevention and treatment.

Main Methods:

• A working group was convened to develop these clinical practice recommendations.
• The group synthesized existing evidence and clinical expertise to formulate guidelines.

Main Results:

• Emetogenic risk assessment for RINV identified two primary predictive factors: irradiated anatomical location and concomitant chemotherapy.
• For exclusive radiotherapy, prophylaxis is based on the emetogenic risk of the irradiated site.
• When chemotherapy is combined with radiotherapy, the emetogenic risk is higher, and prophylaxis aligns with chemotherapy-induced nausea and vomiting guidelines.

Conclusions:

• Radiation-induced nausea and vomiting is frequently underdiagnosed and undertreated, highlighting a gap in clinical practice.
• Prompt identification and effective management of RINV are crucial for improving patient outcomes and adherence to treatment.
• Implementing standardized guidelines is essential for optimizing the care of patients experiencing RINV.